NLA Meeting Highlights

NLA Meeting Highlights

From Vegas to New York, the NLA Highlights Programs are comprehensive reviews of the most popular presentations from our previous meetings. Below you will find a list a meeting highlights from past events. Please feel free to review the presentations.

2021 Spring Clinical Lipid Update

  • Exploring the Systems of Care in ASCVD Management, a healthcare industry panel discussion from the NLA

2020 Scientific Sessions Late-Breakers - Virtual

  • First Human Trial of a Loading Dose of Icosapent Ethyl in Patients with COVID-19: Primary Results of the VASCEPA COVID-19 CardioLink-9 Randomized Trial, presented by Deepak L Bhatt, MD, MPH
  • Reductions in lipoprotein(a) with inclisiran– Analysis from ORION-10 and ORION-11, presented by Frederick Raal, FRCP, FCP(SA), Cert Endo, MMED, PhD
  • EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (Encore Presentation), presented by Michael Miller, MD, FACC, FAHA

2018 Scientific Sessions - Las Vegas, NV

  • CRISPR-Cas9 genome editing for treatment of atherogenic dyslipidemia
  • Update on Clinical Trials: How Will This Affect Practice in the Future?
  • Resistant Hypertension: A Practical Approach to the Guidelines
  • These activity highlights supported by Alexion Pharmaceuticals, Inc.

2017 Spring Clinical Lipid Update - Phoenix, AZ

  • Bariatric Surgery: What a Lipidologist Needs to Know
  • Lipodystrophy
  • Cream of Tomato Soup" Blood: What's the Skinny on FCS and Other Chylomicronemic States?
  • Cholesterol Screening in Children and Young Adults. Where are we going?

2016 Fall Clinical Lipid Update - Amelia Island, FL

  • Noninvasive Imaging for Atherosclerosis Regression
  • Identification of Rare Triglyceride Disorders
  • Therapeutic Options for Triglyceride Lowering
  • Is Lower Better for LDL or is there a “Sweet Spot”

2016 Scientific Sessions - New Orleans, LA

  • Uncommon Dyslipidemias with Common Presentations
  • Human Genetics and CV Risk Assessment
  • Lipoprotein(a) as a Cause of Cardioborbobbvascular Disease
  • Management of FH in Pregnancy: An art or an oxymoron?
  • Gut Microbiota and Atherothrombotic Heart Disease
  • Updates to the 2016 NLA Annual Summary - Secrets Revealed

2016 Spring Clinical Lipid Update - San Diego, CA

  • PCSK9 Inhibitors: Practical Aspects of their use in Patients with Familial Hypercholesterolemia
  • Key Clinical Lipidology Publications: 2015-16
  • Should PCSK9 Inhibitors be Used in Statin Intolerant Patients?
  • PCSK9 Inhibitors: Impact on the Management of LDL Apheresis Candidates and LDL Apheresis Patients

2015 Fall Clinical Lipid Update - Pittsburgh, PA

  • Keeping NLA Members Up-to-Date: Key Articles for the 2016 NLA Annual Summary
  • NLA Recommendations for Patient-Centered Management of Dyslipidemia- Part 2
  • Statin Intolerance as a Barrier to Atherosclerotic Disease Risk Reduction

2015 Scientific Sessions - Chicago, IL

  • NLA Recommendations for Management of Special Populations
  • New Evidence & Outcomes: Information Lipidologists Need to Know
  • New Evidence & Outcomes: Information Lipidologists Need to Know
  • Hypertension: How New Guidelines Should Change Your Practice?
  • Case Discussions: Treatment Strategies for High Risk Populations
  • South Asian Ethnicity - Management and Associated Risk

2015 Spring CLU - Denver, CO

  • Two Different Prevention Approaches Two Different Perspectives
  • Inflammation, Risk Prediction, and the Prevention of ASCVD
  • Clinical Management of Hypertriglyceridemia: State of the Art 2015
  • ApoB in Risk Assessment and the Diagnosis and Treatment of the Atherogenic Dyslipoproteinemias

2014 Fall CLU - Indianapolis, IN

  • NLA Recommendations for Patient-Centered Management of Dyslipidemia
  • Data Supported Evidence for Differences in the ACC/AHA Guidelines and NLA Recommendations for Dyslipidemia Management
  • Current & Future Triglyceride Pharmaceuticals
  • Hypertriglyceridemia Awareness Survey Results
  • Nutrition in Hypertriglyceridemia: Choosing the 'Right' Diet for the 'Right' Patient
  • Are Triglycerides a Cardiovascular Risk Factor?

2014 Scientific Sessions - Orlando, FL

  • 2014 NLA Statin Safety Task Force
  • Effect of Statins on Exercise Performance
  • A Short History of PCSK9 - From Discovery to Clinical Trials
  • Familial Hypercholesterolemia & Pregnancy
  • Understanding US Lipid Guidelines 2013
  • IAS Position Paper: Global Recommendations for the Management of Dyslipidemia

2014 Spring Clinical Lipid Update - Maui, HI

  • Keynote: Guidelines for Lipid Management in 2014
  • HDL: State of the Lipoprotein
  • Omega 3's and Cardiovascular Disease: High versus Low Dose?

2013 Fall Clinical Lipid Update - Baltimore, MD

  • Keynote: HDL Review
  • Is Raising HDL Dead or Not?
  • Genetics of Familial Hypercholesterolemia
  • Genetic Testing - Where are we? Nuts & Bolts of Testing
  • Cardiometabolic Consequences of Sitting Time

2013 Scientific Sessions - Las Vegas, NV

  • Promise and Pitfalls of Lifetime Risk Assessment for CVD
  • NLA HDL Consensus Statement
  • DHA and the Brain: Is it an Essential Nutrient?
  • Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents
  • Personalize Antiplatelet Therapy: State of the Art
  • Obesity, Adiposity, and Dyslipidemia: A Consensus Statement from the NLA
  • Statin Therapy and Incident Diabetes
  • Preparing for Guidelines in 2013

2013 Spring Clinical Lipid Update - New Orleans, LA

  • Gender Differences in CVD Risk Management
  • Untangling the "Heavy" Cardiovascular Burden of Obesity
  • Pregnancy and Dyslipidemia: A Window of Future Health
  • Understanding and Communicating Risk

2012 Scientific Sessions - Scottsdale, AZ

  • The Need to Reduce Sodium in the U.S. Diet
  • Debate Part 1 - Is High-fructose Corn Syrup a Problem?
  • Debate Part 2 - Is High-fructose Corn Syrup a Problem?
  • Statin Therapy and New Onset Diabetes Mellitus
  • Clinical Decision Making: Taking COURAGE to AIM-HIGH
  • The High-Risk Plaque (HRP) Initiative
  • Debate Part 1 - EPA and DHA
  • Debate Part 2 - EPA and DHA
  • Characterizing Cardiovascular Risk in Hispanic Americans

2012 Spring Clinical Lipid Update - San Diego, CA

  • The Problem Patient: Managing Statin Myalgias
  • Beyond Diet Wars: Practical Advice for Your Patient
  • NonHDL and Diabetic Dyslipidemia: A Clinician's Perspective
  • HDL-C: Should We Continue to AIM-HIGH

2011 Scientific Sessions - New York City, NY

  • Clinical Trial Updates Impacting Your Practice
  • The Impact of Prescription Switching on LDL-C Goal Attainment
  • Genetic Susceptibility to Statin-Induced Myopathy
  • The Case For A Low-Fat/Good Carbohydrate Diet
  • HDL Functionality: How Do We Measure It and Is It Relevant
  • What Do Simple Genetics Tell Us About Complex Diseases?
  • Common Etiologies of Hypertriglyceridemia
  • Novel Therapies on the Horizon
  • CKD in the Light of The SHARP Trial



Publish Date: 
Thursday, July 7, 2016 - 10:45

This page was last updated: Mar 08, 2021